Specific microbicides in the prevention of HIV infection
Article first published online: 27 OCT 2011
© 2011 The Association for the Publication of the Journal of Internal Medicine
Journal of Internal Medicine
Volume 270, Issue 6, pages 509–519, December 2011
How to Cite
Kelly, C. G. and Shattock, R. J. (2011), Specific microbicides in the prevention of HIV infection. Journal of Internal Medicine, 270: 509–519. doi: 10.1111/j.1365-2796.2011.02454.x
- Issue published online: 20 NOV 2011
- Article first published online: 27 OCT 2011
- Accepted manuscript online: 14 SEP 2011 06:39PM EST
- clinical trial;
- combination microbicides;
- drug formulation;
Abstract. Kelly CG, Shattock RJ (Dental Institute, King’s College London, London; and Imperial College, London; UK). Specific microbicides in the prevention of HIV infection (Symposium). J Intern Med 2011; doi: 10.1111/j.1365-2796.2011.02454.x.
Microbicides are products that are designed for application at vaginal or rectal mucosae to inhibit or block early events in HIV infection and thereby prevent transmission of HIV. Currently, the most advanced microbicides in the development pipeline are based on highly active anti-retroviral drugs (ARVs). Significant protection of women by vaginally applied tenofovir gel, demonstrated in the CAPRISA 004 trial, has provided proof-of-concept that microbicides can be effective. The rationale for investigating ARVs and other compounds as vaginal or rectal microbicides is discussed together with approaches to improve efficacy by the development of combination microbicides and by new formulations that may increase user acceptance.